The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Sigilon Therapeutics, Inc(NASDAQ:SGTX) 
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is als...
Share this website to your friends
Sigilon Therapeutics Days Receivable Outstanding ttm (DSO)
Sigilon Therapeutics Op Cashflow Per Share ttm
Sigilon Therapeutics Free Cashflow Per Share ttm
Sigilon Therapeutics Cash Per Share ttm
Sigilon Therapeutics P/S ratio ttm
Sigilon Therapeutics (GAAP) P/E ratio ttm
Sigilon Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.